NRx Pharmaceuticals has reported that its investigational drug, Zyesami (aviptadil), statistically significantly prevented a steep surge in cytokines or cytokine storm in Covid-19 patients in Phase IIb/III trial.
JERUSALEM (Reuters) -Israel is partnering with U.S.-based NRx Pharmaceuticals to complete trials and commercialize the Israeli-developed COVID-19 vaccine BriLife.